نتایج جستجو برای: miltefosine

تعداد نتایج: 701  

2016
Ru Fang Xudong Zhu Yaqin Zhu Xing Tong Kexue Li Hui Bai Xiaoyu Li Jingjing Ben Hanwen Zhang Qing Yang Qi Chen

BACKGROUND AND PURPOSE It has been accepted that AMPK (Adenosine monophosphate-activated protein kinase) activation exhibits many beneficial effects on glucolipid metabolism. Lysophosphatidylcholine (LPC) is an important lysophospholipid which can improve blood glucose levels in diabetic mice and attenuate inflammation by activating AMPK signal pathway in macrophages. Synthetic alkylphospholipi...

Journal: :Antimicrobial agents and chemotherapy 2004
Navin K Verma Chinmoy S Dey

Miltefosine causes leishmanial death, but the possible mechanism(s) of action is not known. The mode of action of miltefosine was investigated in vitro in Leishmania donovani promastigotes as well as in extra- and intracellular amastigotes. Here, we demonstrate that miltefosine induces apoptosis-like death in L. donovani based on observed phenomena such as nuclear DNA condensation, DNA fragment...

Journal: :Revista da Sociedade Brasileira de Medicina Tropical 2014
Ana Angélica Amorim Santarem Gabriel Frizon Greggianin Rafaela Garcia Debastiani Jefferson Bruno Pereira Ribeiro Demerson Andre Polli Raimunda Nonata Ribeiro Sampaio

INTRODUCTION The treatment of leishmaniasis ischallenging, given the difficulties in drug administration and resistance. Therefore, we chose to test the efficacy of miltefosine combined with pentoxifylline. METHODS Twenty-seven isogenic C57Bl/6 mice were infected with Leishmania (Leishmania) amazonensis, and equally divided into three groups: miltefosine (200mg/kg/day), miltefosine (200mg/kg/...

2016
Monique Wasunna Simon Njenga Manica Balasegaram Neal Alexander Raymond Omollo Tansy Edwards Thomas P. C. Dorlo Brima Musa Mohammed Hassan Sharaf Ali Mohammed Yasein Elamin George Kirigi Rashid Juma Anke E. Kip Gerard J. Schoone Asrat Hailu Joseph Olobo Sally Ellis Robert Kimutai Susan Wells Eltahir Awad Gasim Khalil Nathalie Strub Wourgaft Fabiana Alves Ahmed Musa

BACKGROUND SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBisome and miltefosine are safe and effective in India, but there are no published data from trials of combination therapies including these drugs from Africa. METHODS A phase II open-label, non-compar...

Journal: :The Journal of infectious diseases 2011
Debanjan Mukhopadhyay Nilay Kanti Das Susmita Roy Sunanda Kundu J N Barbhuiya Mitali Chatterjee

BACKGROUND The increasing incidence of unresponsiveness to antimonials in leishmaniasis prompted the use of newer drugs such as miltefosine. Miltefosine influences macrophage effector functions, but its effect on patients with post kala-azar dermal leishmaniasis (PKDL) has not been evaluated. METHODOLOGY The immunomodulatory activity of miltefosine was evaluated in patients with PKDL by study...

Journal: :The Journal of antimicrobial chemotherapy 2009
Julia Walochnik Andreas Obwaller Florian Gruber Michael Mildner Erwin Tschachler Miranda Suchomel Michael Duchêne Herbert Auer

OBJECTIVES Acanthamoebae can cause infections of several organs, including eye, skin, lung and brain. Except for Acanthamoeba keratitis, these infections are linked to immunodeficiency. Treatment is generally problematic, due to the lack of sufficiently effective and also easily manageable drugs. In a previous study we discovered that miltefosine (hexadecylphosphocholine) is highly active again...

2014
Auke P. Verhaar Manon E. Wildenberg Maikel P. Peppelenbosch Daniel W. Hommes Gijs R. van den Brink

Miltefosine is an ether lipid that was initially developed for cancer treatment in the early 1980s. Miltefosine largely failed development for oncology, although it was approved for the topical treatment of breast cancer metastasis. It was subsequently discovered that miltefosine is a highly effective treatment of visceral Leishmaniasis, a parasitic disease that affects millions worldwide and c...

2016
Adriano C. Coelho Cristiana T. Trinconi Carlos H. N. Costa Silvia R. B. Uliana

Miltefosine is the most efficacious oral drug available for the treatment of leishmaniasis. While miltefosine has been in use in India for the treatment of visceral leishmaniasis for a number of years [1], its application to the treatment of cutaneous leishmaniasis is still under investigation [2–4]. We recently reported that miltefosine was effective in the treatment of Leishmania amazonensis ...

Journal: :Antimicrobial agents and chemotherapy 2018
Emily G Armitage Amjed Q I Alqaisi Joanna Godzien Imanol Peña Alison J Mbekeani Vanesa Alsonso-Herranz Ángeles López-Gonzálvez Julio Martín Raquel Gabarro Paul W Denny Michael P Barrett Coral Barbas

With the World Health Organization reporting over 30,000 deaths and 200-400,000 new cases annually, visceral Leishmaniasis is a serious disease affecting some of the world's poorest people. As drug resistance continues to rise, there is a huge unmet need to improve treatment. Miltefosine remains one of the main treatments for Leishmaniasis, yet its mode of action (MoA) is still unknown. Underst...

Journal: :The Journal of pharmacology and experimental therapeutics 2014
Auke P Verhaar Manon E Wildenberg Maikel P Peppelenbosch Daniel W Hommes Gijs R van den Brink

Miltefosine is an ether lipid that was initially developed for cancer treatment in the early 1980s. Miltefosine largely failed development for oncology, although it was approved for the topical treatment of breast cancer metastasis. It was subsequently discovered that miltefosine is a highly effective treatment of visceral Leishmaniasis, a parasitic disease that affects millions worldwide and c...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید